Hims & Hers Health, Inc.’s (HIMS) investors are reaping some gains from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have gained 31.1% since Nov. 1, outperforming the industry’s 14.6% gain. In the same time frame, the stock outperformed the sector and S&P 500’s 0.6% decline and 4.6% growth, respectively. The company reported its third-quarter 2024 earnings on Nov. 4.Another major development from HIMS in recent months includes the announcement of access to the most c ...

The healthcare company is on fire, and it's still cheap by many measures.Shares of Hims & Hers Health (HIMS 19.09%) have been on fire over the past year, but they're not expensive by most valuation metrics, especially when you consider the company's high growth rate. How much room is left to run? That's what Travis Hoium discusses in this video.*Stock prices used were end-of-day prices of Nov. 11, 2024. The video was published on Nov. 11, 2024. ...

My goal is to help you find the companies of tomorrow.I am a long-term growth investor in search of innovative companies that make the world a better place. My investment strategy revolves around finding what I call "divergent stocks" — disruptive companies that have strong fundamentals and long growth runways, but depressing prices.You can find me on YouTube as well:https://www.youtube.com/@riyadosofianAnalyst’s Disclosure: I/we have a beneficial long position in the shares of HIMS, PLTR either through sto ...

Editor's note: Seeking Alpha is proud to welcome Julian Fuchs as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.As a 20-year-old student passionate about stock analysis, I provide in-depth equity research and market insights. With a solid grasp of financial trends, I aim to offer actionable investment ideas and identify growth and value opportunities. F ...

Hims & Hers Health, Inc. (HIMS) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company. Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings e ...

Hims & Hers strong performance involves much more than just GLP-1 drugs.Hims & Hers Health (HIMS 0.85%) reported another blowout quarter recently, but the stock didn't get the type of pop that might typically be seen with such an earnings beat. The stock has been very volatile this year, with its shares trading up and down on any news related to GLP-1 weight loss drugs. So far, the news has generally been good and the stock has still climbed by more than 225% over the past year.Let's take a closer look at t ...

The company expects to enjoy many GLP-1 tailwinds in 2025. In today's video, I will talk about Hims and Hers Health's (HIMS 8.37%) third-quarter earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock prices used were from the trading day of Nov. 5, 2024. The video was published on Nov. 5, 2024. ...

Most investors would look at an earnings announcement as a past event, connecting the current price action in the stock and reacting to the results as something that cannot be taken advantage of, thinking that it is now too late to get into action. This might be the case for shares of Hims & Hers Health Inc. NYSE: HIMS, as the stock is now rallying by over 6% the morning after the company reported its quarterly earnings. Hims & Hers Health Today HIMS Hims & Hers Health $20.64 -0.12 (-0.58%) 52-Week Range $6 ...

Core Insights - Hims reported third-quarter results that exceeded analysts' expectations, with a significant revenue increase driven by weight-loss drugs [1][2] - The company plans to launch a generic version of Novo Nordisk's diabetes and weight-loss drug as early as 2025 [1][4] - Bank of America raised its price target for Hims' stock, indicating potential for continued user growth [1][3] Financial Performance - Hims achieved a 77% year-over-year revenue increase, reaching $401.6 million [2] - Revenue from weight-loss drugs is estimated to be between $63 million and $70 million for the latest quarter, showing growth from the previous quarter [3] Strategic Plans - Hims intends to increase marketing spending in the fourth quarter to drive user growth [3] - The company has confirmed a core supplier for the upcoming generic drug and is in the process of completing test and batch validation [4]

Hims & Hers Health, Inc. (HIMS) delivered an earnings per share (EPS) of 32 cents in third-quarter 2024 against the year-ago period's loss of 4 cents per share. The metric was in line with the Zacks Consensus Estimate. HIMS' Revenues in Detail Hims & Hers registered revenues of $401.6 million in the third quarter, up 77.1% year over year. The figure beat the Zacks Consensus Estimate by 4.5%. Solid revenues from both Online and Wholesale channels drove the top line. Shares of this company gained nearly 11.4% ...